The online version of this article (doi:10.1007/s40121-014-0046-6) contains supplementary material, which is available to authorized users.
Lower respiratory tract infection (LRTI) is the leading cause of infant mortality globally in post-neonatal infants (i.e., 28–364 days of age). Respiratory syncytial virus (RSV) is the most commonly identified pathogen for infant LRTI and is the second most important cause of death in post-neonatal infants. Despite 50 years of RSV vaccine research, there is still no approved vaccine. Therefore, passive immunity with the monoclonal antibody palivizumab is the sole regulatory-approved option for the prevention of serious LRTI caused by RSV in pediatric patients at high risk of RSV disease.
We conducted a comprehensive systematic literature review of randomized controlled trials (RCTs), open-label non-comparative clinical trials, and prospective observational studies/registries, and summarized the evidence related to the safety, efficacy, and effectiveness of palivizumab.
The efficacy of palivizumab, as measured by the relative reduction in RSV-related hospitalization rate compared with placebo ranged from 39% to 78% (P < 0.05) in the 2 pivotal RCTs. A meta-analysis of the RSV-related hospitalization rate from 5 randomized placebo-controlled trials yielded an overall odds ratio of 0.41 (95% CI, 0.31–0.55) in favor of palivizumab prophylaxis over placebo (P < 0.00001). Low rates of RSV-related hospitalizations were observed in palivizumab recipients consistently over time in more than 42,000 pediatric subjects across 7 RCTs, 4 open-label non-comparative trials, and 8 observational studies/registries conducted in 34 countries. In addition, among palivizumab-prophylaxed subjects with breakthrough RSV LRTI, rates of intensive care unit admission and mechanical ventilation from RSV hospitalization also were low and consistent across studies. With respect to safety, no differences were observed between palivizumab and placebo in the blinded RCTs.
Rates of RSV hospitalizations and RSV hospitalization-related endpoints in pediatric subjects who received prophylaxis with palivizumab were low and constant over time and across RCTs, open-label non-comparative trials, and observational studies/registries.
American Academy of Pediatrics. Summaries of infectious diseases: respiratory syncytial virus. In: Pickering LK, editor. Red book: 2012 report of the committee on infectious diseases. 29th ed. Elk Grove Village: American Academy of Pediatrics; 2012. p. 609–18.
Glezen WP, Taber LH, Frank AL, Kasel JA. Risk of primary infection and reinfection with respiratory syncytial virus. Am J Dis Child. 1986;140:543–6. PubMed
Hall CB, Simoes EA, Anderson LJ. Clinical and epidemiologic features of respiratory syncytial virus. Curr Top Microbiol Immunol. 2013;372:39–57. PubMed
Dawson-Caswell M, Muncie HL Jr. Respiratory syncytial virus infection in children. Am Fam Physician. 2011;83:141–6. PubMed
Graham BS, Anderson LJ. Challenges and opportunities for respiratory syncytial virus vaccines. Curr Top Microbiol Immunol. 2013;372:391–404. PubMed
Kapikian AZ, Mitchell RH, Chanock RM, Shvedoff RA, Stewart CE. An epidemiologic study of altered clinical reactivity to respiratory syncytial (RS) virus infection in children previously vaccinated with an inactivated RS virus vaccine. Am J Epidemiol. 1969;89:405–21. PubMed
Kim HW, Canchola JG, Brandt CD, et al. Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. Am J Epidemiol. 1969;89:422–34. PubMed
Chin J, Magoffin RL, Shearer LA, Schieble JH, Lennette EH. Field evaluation of a respiratory syncytial virus vaccine and a trivalent parainfluenza virus vaccine in a pediatric population. Am J Epidemiol. 1969;89:449–63. PubMed
Synagis ® (palivizumab). Full prescribing information, MedImmune, LLC, Gaithersburg, MD, 2014. Available from: http://www.medimmune.com/docs/default-source/pdfs/prescribing-information-for-synagis.pdf. Accessed September 15, 2014.
The IMpact-RSV Study Group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics. 1998;102:531–7. CrossRef
Robbie GJ, Makari D, Harris B, Losonsky GA, Jafri HS. Randomized, double-blind study of the pharmacokinetics and safety of palivizumab liquid formulation compared with lyophilized formulation. Infect Dis Ther. 2014 (in press).
Robinson JL, Canadian Paediatric Society, Infectious Diseases and Immunization Committee. Preventing respiratory syncytial virus infections. Paediatr Child Health. 2011;16:488–90.
German Society for Paediatric Infectious Diseases (DGPI), German Society of Pediatric Cardiology (DGPK), Society of Pediatric Pneumology (GPP), Society of Neonatology and Pediatric Intensive Care Medicine (GNPI). RSV prophylaxis with palivizumab in high-risk children. Updated German national guidelines 2008. Monatsschr Kinderheilkd. 2009;157:61–4. CrossRef
Figueras Aloy J, Carbonell Estrany X, Comite de Estandares de la Sociedad Espanola de Neonatologia. Recommendations for the use of palivizumab in the prevention of respiratory syncytial virus infection in late preterm infants (32(1) to 35(0) weeks of gestation). An Pediatr (Barc). 2010;73:98.e1-4. PubMed
American Academy of Pediatrics Committee on Infectious Diseases, American Academy of Pediatrics Bronchiolitis Guidelines Committee. Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection. Pediatrics. 2014;134:415–20. CrossRef
Lesnick BL, Huddle ME, Shi S, Bomar R. Efficacy of palivizumab use in high-risk infants, 1999–2003. Chest. 2003;124:73S. CrossRef
Nishida H, Fujimura M, Takeuchi Y, et al. Prevention of RS virus infection (the guidelines for the use of palivizumab in Japan). J Jpn Pediatr Soc. 2002;106:1288–92.
Andabaka T, Nickerson JW, Rojas-Reyes MX, et al. Monoclonal antibody for reducing the risk of respiratory syncytial virus infection in children. Cochrane Database Syst Rev. 2013;4:CD006602. PubMed
- Safety and Effectiveness of Palivizumab in Children at High Risk of Serious Disease Due to Respiratory Syncytial Virus Infection: A Systematic Review
Lim Kai Toh
- Springer Healthcare
Neu im Fachgebiet Innere Medizin
Meistgelesene Bücher aus der Inneren Medizin
Mail Icon II